PDK4 and diffuse large B-cell lymphoma: These results demonstrate that the aCD20@ExoCTX/siPDK4 exosome nanoparticle complex effectively inhibits PDK4 and, through dephosphorylation of nuclear HDAC8, upregulates CD20 expression, thereby reversing the molecular mechanism of rituximab resistance in DLBCL.